Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Blood Neoplasia Pub Date : 2024-09-16 DOI:10.1016/j.bneo.2024.100042

Eunice Lai ∗ , Yu Yang Soon ∗ , Ainsley Ryan Yan Bin Lee , Shi Yin Wong , Cinnie Yentia Soekojo , Melissa Ooi , Wee Joo Chng , Sanjay de Mel

{"title":"Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma","authors":"Eunice Lai ∗ , Yu Yang Soon ∗ , Ainsley Ryan Yan Bin Lee , Shi Yin Wong , Cinnie Yentia Soekojo , Melissa Ooi , Wee Joo Chng , Sanjay de Mel","doi":"10.1016/j.bneo.2024.100042","DOIUrl":null,"url":null,"abstract":"<div><h3>Abstract</h3><div>Lenalidomide, ixazomib, and daratumumab have been proposed as maintenance therapies for patients with newly diagnosed multiple myeloma (MM; NDMM). There are, however, no randomized controlled trials (RCTs) comparing them. We conducted a network meta-analysis (NMA) of RCTs comparing these agents against placebo in NDMM. A Bayesian NMA model was used to assess the relative effects of competing treatments on progression-free survival (PFS) and overall survival (OS) in 9 studies including 4115 patients with transplant-eligible MM (TEMM) and 1689 patients with non–transplant-eligible MM (NTEMM). Lenalidomide and daratumumab but not ixazomib were associated with improved PFS compared with placebo in patients with TEMM (lenalidomide [hazard ratio (HR), 0.46; 95% credible interval (CrI), 0.36-0.56]; daratumumab [HR, 0.49; 95% Crl, 0.32-0.76]; and ixazomib [HR, 0.72; 95% CrI, 0.46-1.12]) and those with NTEMM (lenalidomide [HR, 0.46; 95% CrI, 0.29-0.75] and ixazomib [HR, 0.69; 95% CrI, 0.43-1.18]). The PFS benefit for daratumumab was present regardless of whether daratumumab-based induction therapy was received. None of the agents showed an OS benefit, and PFS benefits were not seen in patients with high-risk cytogenetics. Lenalidomide was associated with second malignancies, ixazomib with thrombocytopenia, and daratumumab with pneumonia. We propose that lenalidomide remains the maintenance therapy of choice for NDMM.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100042"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Neoplasia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950328024000426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Lenalidomide, ixazomib, and daratumumab have been proposed as maintenance therapies for patients with newly diagnosed multiple myeloma (MM; NDMM). There are, however, no randomized controlled trials (RCTs) comparing them. We conducted a network meta-analysis (NMA) of RCTs comparing these agents against placebo in NDMM. A Bayesian NMA model was used to assess the relative effects of competing treatments on progression-free survival (PFS) and overall survival (OS) in 9 studies including 4115 patients with transplant-eligible MM (TEMM) and 1689 patients with non–transplant-eligible MM (NTEMM). Lenalidomide and daratumumab but not ixazomib were associated with improved PFS compared with placebo in patients with TEMM (lenalidomide [hazard ratio (HR), 0.46; 95% credible interval (CrI), 0.36-0.56]; daratumumab [HR, 0.49; 95% Crl, 0.32-0.76]; and ixazomib [HR, 0.72; 95% CrI, 0.46-1.12]) and those with NTEMM (lenalidomide [HR, 0.46; 95% CrI, 0.29-0.75] and ixazomib [HR, 0.69; 95% CrI, 0.43-1.18]). The PFS benefit for daratumumab was present regardless of whether daratumumab-based induction therapy was received. None of the agents showed an OS benefit, and PFS benefits were not seen in patients with high-risk cytogenetics. Lenalidomide was associated with second malignancies, ixazomib with thrombocytopenia, and daratumumab with pneumonia. We propose that lenalidomide remains the maintenance therapy of choice for NDMM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多发性骨髓瘤的来那度胺、伊沙佐米或达拉曲单抗维持疗法

摘要来那度胺、伊沙佐米和达拉曲单抗已被提议作为新诊断多发性骨髓瘤（MM；NDMM）患者的维持疗法。然而，目前还没有随机对照试验（RCT）对它们进行比较。我们对在 NDMM 中比较这些药物与安慰剂的 RCT 进行了网络荟萃分析（NMA）。我们使用贝叶斯NMA模型评估了9项研究中竞争治疗对无进展生存期（PFS）和总生存期（OS）的相对影响，这些研究包括4115名符合移植条件的MM（TEMM）患者和1689名不符合移植条件的MM（NTEMM）患者。与安慰剂相比，来那度胺和达拉曲单抗改善了TEMM患者的PFS（来那度胺[危险比（HR），0.46；95%可信区间（CrI），0.36-0.56]；daratumumab[HR，0.49；95% Crl，0.32-0.76]；ixazomib[HR，0.72；95% CrI，0.46-1.12]]）和NTEMM患者（来那度胺[HR，0.46；95% CrI，0.29-0.75]和ixazomib[HR，0.69；95% CrI，0.43-1.18]）。无论是否接受了基于达拉土单抗的诱导治疗，达拉土单抗的PFS获益都是存在的。没有一种药物显示出OS获益，高危细胞遗传学患者也没有PFS获益。来那度胺与二次恶性肿瘤有关，伊沙佐米与血小板减少有关，达拉土单抗与肺炎有关。我们建议来那度胺仍是NDMM的首选维持疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Neoplasia

自引率

0.00%

发文量